Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells

Cell Death and Differentiation

Volumn 21, Issue 2, 2014, Pages 258-269

  Venere, M ^a   Hamerlik, P ^b,c   Wu, Q ^a   Rasmussen, R D ^b   Song, L A ^a   Vasanji, A ^d   Tenley, N ^d   Flavahan, W A ^a   Hjelmeland, A B ^a,e   Bartek, J ^b,c   Rich, J N ^a,e  

^a LERNER RESEARCH INSTITUTE   (United States)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^c PALACKÝ UNIVERSITY   (Czech Republic)

^d ImageIQ Inc   (United States)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cancer stem cell; DNA repair; glioma; PARP; radioresistance

Indexed keywords

NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; OLAPARIB; REACTIVE OXYGEN METABOLITE; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER RADIOTHERAPY; CANCER STEM CELL; CELL RENEWAL; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DNA REPAIR; DRUG EFFICACY; DRUG TARGETING; FLOW CYTOMETRY; GLIOBLASTOMA; GLIOBLASTOMA INITIATING CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IRRADIATION; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SINGLE STRANDED DNA BREAK; STRESS; TUMOR VOLUME; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DNA DAMAGE; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; NUDE MOUSE; PATHOLOGY; STRUCTURE ACTIVITY RELATION;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; CELL SURVIVAL; DNA DAMAGE; DNA REPAIR; DOSE-RESPONSE RELATIONSHIP, DRUG; GLIOBLASTOMA; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASTIC STEM CELLS; PHENOTYPE; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASES; REACTIVE OXYGEN SPECIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84892430577     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2013.136     Document Type: Article

References (54)

1. Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Clement PM et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 2010; 28: 2712-2718.
2. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444: 756-760. (Pubitemid 44949604)
3. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004; 64: 7011-7021. (Pubitemid 39331011)
4. Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH, Bronner-Fraser M et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA 2003; 100: 15178-15183. (Pubitemid 37518036)
5. Ignatova TN, Kukekov VG, Laywell ED, Suslov ON, Vrionis FD, Steindler DA. Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia 2002; 39: 193-206.
6. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63: 5821-5828. (Pubitemid 37187480)
7. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T et al. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401. (Pubitemid 39551674)
8. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR et al. Analysis of gene expression and chemoresistance of CD133\+ cancer stem cells in glioblastoma. Mol Cancer 2006; 5: 67.
9. Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 2006; 66: 7843-7848. (Pubitemid 44299144)
10. Cheng L, Wu Q, Guryanova OA, Huang Z, Huang Q, Rich JN et al. Elevated invasive potential of glioblastoma stem cells. Biochem Biophys Res Commun 2011; 406: 643-648.
11. Tamura K, Aoyagi M, Wakimoto H, Ando N, Nariai T, Yamamoto M et al. Accumulation of CD133-positive glioma cells after high-dose irradiation by Gamma Knife surgery plus external beam radiation. J Neurosurg 2010; 113: 310-318.
12. Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 2009; 8: 806-823.
13. Pajonk F, Vlashi E, McBride WH. Radiation resistance of cancer stem cells: the 4 R's of radiobiology revisited. Stem Cells 2010; 28: 639-648.
14. Chang CJ, Hsu CC, Yung MC, Chen KY, Tzao C, Wu WF et al. Enhanced radiosensitivity and radiation-induced apoptosis in glioma CD133-positive cells by knockdown of SirT1 expression. Biochem Biophys Res Commun 2009; 380: 236-242.
15. Wang J, Wakeman TP, Lathia JD, Hjelmeland AB, Wang XF, White RR et al. Notch promotes radioresistance of glioma stem cells. Stem Cells 2010; 28: 17-28.
16. Yang YP, Chang YL, Huang PI, Chiou GY, Tseng LM, Chiou SH et al. Resveratrol suppresses tumorigenicity and enhances radiosensitivity in primary glioblastoma tumor initiating cells by inhibiting the STAT3 axis. J Cell Physiol 2012; 227: 976-993.
17. Hamerlik P, Lathia JD, Rasmussen R, Wu Q, Bartkova J, Lee M et al. Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth. J Exp Med 2012; 209: 507-520.
18. Facchino S, Abdouh M, Chatoo W, Bernier G. BMI1 confers radioresistance to normal and cancerous neural stem cells through recruitment of the DNA damage response machinery. J Neurosci 2010; 30: 10096-10111.
19. Cheng L, Wu Q, Huang Z, Guryanova OA, Huang Q, Shou W et al. L1CAM regulates DNA damage checkpoint response of glioblastoma stem cells through NBS1. EMBO J 2011; 30: 800-813.
20. Svendsen A, Verhoeff JJ, Immervoll H, Brogger JC, Kmiecik J, Poli A et al. Expression of the progenitor marker NG2/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastoma. Acta Neuropathol 2011; 122: 495-510.
21. Calabrese CR, Almassy R, Barton S, Batey MA, Calvert AH, Canan-Koch S et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 2004; 96: 56-67. (Pubitemid 38180960)
22. Chalmers A, Johnston P, Woodcock M, Joiner M, Marples B. PARP-1, PARP-2, and the cellular response to low doses of ionizing radiation. Int J Radiat Oncol Biol Phys 2004; 58: 410-419. (Pubitemid 38142466)
23. Dungey FA, Caldecott KW, Chalmers AJ. Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90. Mol Cancer Ther 2009; 8: 2243-2254.
24. Dungey FA, Loser DA, Chalmers AJ. Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential. Int J Radiat Oncol Biol Phys 2008; 72: 1188-1197.
25. Oplustilova L, Wolanin K, Mistrik M, Korinkova G, Simkova D, Bouchal J et al. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment. Cell Cycle 2012; 11: 20.
26. Russo AL, Kwon HC, Burgan WE, Carter D, Beam K, Weizheng X et al. In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016. Clin Cancer Res 2009; 15: 607-612.
27. van Vuurden DG, Hulleman E, Meijer OL, Wedekind LE, Kool M, Witt H et al. PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation. Oncotarget 2011; 2: 984-996.
28. Albert JM, Cao C, Kim KW, Willey CD, Geng L, Xiao D et al. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res 2007; 13: 3033-3042. (Pubitemid 46849580)
29. Donawho CK, Luo Y, Penning TD, Bauch JL, Bouska JJ, Bontcheva-Diaz VD et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNAdamaging agents in preclinical tumor models. Clin Cancer Res 2007; 13: 2728-2737. (Pubitemid 46795129)
30. Kelland LR, Tonkin KS. The effect of 3-aminobenzamide in the radiation response of three human cervix carcinoma xenografts. Radiother Oncol 1989; 15: 363-369. (Pubitemid 19218058)
31. Khan K, Araki K, Wang D, Li G, Li X, Zhang J et al. Head and neck cancer radiosensitization by the novel poly(ADP-ribose) polymerase inhibitor GPI-15427. Head Neck 2010; 32: 381-391.
32. Senra JM, Telfer BA, Cherry KE, McCrudden CM, Hirst DG, O'Connor MJ et al. Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft. Mol Cancer Ther 2011; 10: 1949-1958.
33. Underhill C, Toulmonde M, Bonnefoi H. A review of PARP inhibitors: from bench to bedside. Ann Oncol 2011; 22: 268-279.
34. Bartkova J, Hamerlik P, Stockhausen MT, Ehrmann J, Hlobilkova A, Laursen H et al. Replication stress and oxidative damage contribute to aberrant constitutive activation of DNA damage signalling in human gliomas. Oncogene 2010; 29: 5095-5102.
35. Eyler CE, Wu Q, Yan K, MacSwords JM, Chandler-Militello D, Misuraca KL et al. Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2. Cell 2011; 146: 53-66.
36. Lathia JD, Gallagher J, Heddleston JM, Wang J, Eyler CE, Macswords J et al. Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell 2010; 6: 421-432.
37. Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 2009; 15: 501-513.
38. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006; 9: 391-403. (Pubitemid 43668737)
39. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009; 458: 780-783.
40. Groth A, Corpet A, Cook AJ, Roche D, Bartek J, Lukas J et al. Regulation of replication fork progression through histone supply and demand. Science 2007; 318: 1928-1931.
41. Raderschall E, Golub EI, Haaf T. Nuclear foci of mammalian recombination proteins are located at single-stranded DNA regions formed after DNA damage. Proc Natl Acad Sci USA 1999; 96: 1921-1926. (Pubitemid 29117843)
42. Jamal M, Rath BH, Tsang PS, Camphausen K, Tofilon PJ. The brain microenvironment preferentially enhances the radioresistance of CD133(\+) glioblastoma stem-like cells. Neoplasia 2012; 14: 150-158.
43. Vlashi E, Lagadec C, Vergnes L, Matsutani T, Masui K, Poulou M et al. Metabolic state of glioma stem cells and nontumorigenic cells. Proc Natl Acad Sci USA 2011; 108: 16062-16067.
44. Le Belle JE, Orozco NM, Paucar AA, Saxe JP, Mottahedeh J, Pyle AD et al. Proliferative neural stem cells have high endogenous ROS levels that regulate self-renewal and neurogenesis in a PI3K/Akt-dependant manner. Cell Stem Cell 2011; 8: 59-71.
45. Nitta M, Kozono D, Kennedy R, Stommel J, Ng K, Zinn PO et al. Targeting EGFR induced oxidative stress by PARP1 inhibition in glioblastoma therapy. PLoS One 2010; 5: e10767.
46. Martin-Oliva D, Aguilar-Quesada R, O'Valle F, Munoz-Gamez JA, Martinez-Romero R, Garcia Del Moral R et al. Inhibition of poly(ADP-ribose) polymerase modulates tumorrelated gene expression, including hypoxia-inducible factor-1 activation, during skin carcinogenesis. Cancer Res 2006; 66: 5744-5756. (Pubitemid 43927128)
47. Tentori L, Lacal PM, Muzi A, Dorio AS, Leonetti C, Scarsella M et al. Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis. Eur J Cancer 2007; 43: 2124-2133. (Pubitemid 47380363)
48. Lord CJ, Ashworth A. The DNA damage response and cancer therapy. Nature 2012; 481: 287-294.
49. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012; 483: 570-575.
50. Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim JS et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO J Mol Med 2009; 1: 315-322.
51. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-921. (Pubitemid 40559006)
52. Hu Y, Smyth GK. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods 2009; 347: 70-78.
53. Bliss CI. The toxicity of poisons applied jointly. Ann Appl Biol 1939; 26: 585-615.
54. Greco WR, Bravo G, Parsons JC. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 1995; 47: 331-385.